A previous study on breast cancer demonstrated that silibinin treatment impairs mitochondrial dynamics, decreases ROS levels, and prevents NLRP3 inflammasome activation in MDA-MB-231 cells [56]. This evidence concerns the gene NLRP3 and breast carcinoma.